MabVax Therapeutics Holdings, Inc. (MBVXQ) financial statements (2021 and earlier)

Company profile

Business Address 11535 SORRENTO VALLEY ROAD
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments144125
Cash and cash equivalents144125
Receivables  1   
Prepaid expense0000 
Prepaid expense and other current assets1
Other current assets0000 
Other undisclosed current assets   000
Total current assets:145235
Noncurrent Assets
Property, plant and equipment1100  
Intangible assets, net (including goodwill)7777
Goodwill7777  
Deposits noncurrent assets   0  
Restricted cash and investments     0
Other noncurrent assets0000 
Other undisclosed noncurrent assets   (0)  
Total noncurrent assets:8877 0
TOTAL ASSETS:91212936
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities334201
Accounts payable113100
Accrued liabilities210000
Employee-related liabilities011000
Interest and dividends payable00    
Debt22    
Deferred revenue and credits     0
Other undisclosed current liabilities111111
Total current liabilities:665312
Noncurrent Liabilities
Long-term debt and lease obligation23    
Long-term debt, excluding current maturities23    
Capital lease obligations00    
Liabilities, other than long-term debt00   0
Restructuring reserve     0
Other liabilities00    
Total noncurrent liabilities:23   0
Total liabilities:895313
Temporary equity, carrying amount   2  
Stockholders' equity
Stockholders' equity attributable to parent, including:137423
Common stock0000  
Additional paid in capital112826824555551
Accumulated deficit(111)(78)(61)(25)(554)(548)
Other undisclosed stockholders' equity attributable to parent000400
Total stockholders' equity:137423
TOTAL LIABILITIES AND EQUITY:91212936

Income statement (P&L) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Gross profit: 010  
Operating expenses(18)(17)(19)(9)(5)(8)
Operating loss:(18)(17)(18)(8)(5)(8)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(1)(1)(0)(0)00
Interest and debt expense(1)(1)    
Net loss:(20)(19)(18)(8)(5)(8)
Other undisclosed net income attributable to parent1100  
Net loss attributable to parent:(19)(18)(18)(8)(5)(8)
Preferred stock dividends and other adjustments  (9)(3)  
Other undisclosed net loss available to common stockholders, basic(14) (9)   
Net loss available to common stockholders, diluted:(33)(18)(36)(11)(5)(8)

Comprehensive Income ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(20)(19)(18)(8)(5)(8)
Comprehensive loss, net of tax, attributable to parent:(20)(19)(18)(8)(5)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: